Gender differences in prevalence and associations between cognitive symptoms and suicidal ideation in patients with recurrent major depressive disorder: findings from the Chinese NSSD study

Table 2 Medication treatment of male and female MDD patients with recurrent depression

Medication	Total (n = 1222)	Male (n = 476)	Female (n = 746)	x²	P
SSRIs	819 (67.1)	332 (69.7)	487 (65.4)	2.522	0.112
SNRIs	196 (16.1)	74 (15.5)	122 (16.4)	0.148	0.700
TCAs	64 (5.2)	31 (6.5)	33 (4.4)	2.537	0.111
NaSSAs	74 (6.1)	29 (6.1)	45 (6.0)	0.001	0.970
NDRIs	3 (0.2)	1 (0.2)	2 (0.3)	0.040	0.841
SARIs	24 (2.0)	5 (1.1)	19 (2.6)	3.391	0.066
Mood stabilizer	103 (8.4)	51 (10.7)	52 (7.0)	5.244	0.022^*
Antipsychotics	242 (19.8)	89 (18.7)	153 (20.5)	0.711	0.701
Benzodiazepines	646 (52.9)	247 (51.9)	399 (53.6)	0.324	0.569

Data were presented as number plus rate (n, %). SSRIs, selective serotonin reuptake inhibitors. SNRIs, serotonin-norepinephrine reuptake inhibitors. TCAs, tricyclic antidepressants. NaSSAs, noradrenergic and specific serotonergic antidepressants. NDRIs, norepinephrine-dopamine reuptake inhibitors. SARIs, serotonin antagonist and reuptake inhibitors
^* P < 0.05

ISSN: 1471-244X